Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + polyethylene glycol loxenatide + canagliflozin in high-risk secondary prevention type 2 diabetes with kidney disease
ChiCTR2100045569Phase 4Not yet recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of metformin, polyethylene glycol loxenatide and canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoint: glycated hemoglobin. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
metforminpolyethylene glycol loxenatidecanagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100045569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045569.